Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IJ7O
|
|||
| Former ID |
DNC000928
|
|||
| Drug Name |
Metastat
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acne vulgaris [ICD-11: ED80; ICD-10: L70.0; ICD-9: 706.1] | Phase 1 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H17NO7
|
|||
| Canonical SMILES |
C1C2CC3=C(C(=CC=C3)O)C(=C2C(=O)C4(C1CC(=O)C(=C4O)C(=O)N)O)O
|
|||
| InChI |
1S/C19H17NO7/c20-18(26)14-11(22)6-9-5-8-4-7-2-1-3-10(21)12(7)15(23)13(8)16(24)19(9,27)17(14)25/h1-3,8-9,21,23,25,27H,4-6H2,(H2,20,26)/t8-,9-,19-/m0/s1
|
|||
| InChIKey |
NBRQRXRBIHVLGI-OWXODZSWSA-N
|
|||
| CAS Number |
CAS 15866-90-7
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00001683) A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer. U.S. National Institutes of Health. | |||
| REF 2 | A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res. 2004 Oct 1;10(19):6512-21. | |||
| REF 3 | Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.